Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Medicure Inc. (MCUJF : OTC)

• Company Description    Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $0.81 Daily Weekly Monthly 20 Day Moving Average: 3,852 shares Shares Outstanding: 10.44 (millions) Market Capitalization: $8.49 (millions) Beta: 1.10 52 Week High: $0.97 52 Week Low: $0.44 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.61% -13.48% 12 Week -0.18% -1.98% Year To Date 31.24% 13.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 - 1250 Waverley Street - WINNIPEG,A2 R3T 6C6 CAN ph: 204-487-7412 fax: 204-488-9823 ir@medicure.com http://www.medicure.com

• General Corporate Information    Officers Albert D. Friesen - Chairman and Chief Executive Officer Neil Owens - President and Chief Operating Officer Haaris Uddin - Chief Financial Officer Reuben Saba - Vice-President Arnold Naimark - Director Peer Information Medicure Inc. (GSAC) Medicure Inc. (CASI) Medicure Inc. (ALCD.) Medicure Inc. (OMNN) Medicure Inc. (CGPI.) Medicure Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 58469E408 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 04/24/26 Share - Related Items Shares Outstanding: 10.44 Most Recent Split Date: 11.00 (0.07:1) Beta: 1.10 Market Capitalization: $8.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/24/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.68 Price/Cash Flow: 9.12 Price / Sales: 0.45 EPS Growth vs. Year Ago Period: -280.00% vs. Previous Quarter: -50.00% Sales Growth vs. Year Ago Period: 56.87% vs. Previous Quarter: 22.93% ROE 09/30/25 - -17.91 06/30/25 - -6.65 03/31/25 - -8.74 ROA 09/30/25 - -11.95 06/30/25 - -4.52 03/31/25 - -6.05 Current Ratio 09/30/25 - 1.44 06/30/25 - 1.48 03/31/25 - 1.71 Quick Ratio 09/30/25 - 1.00 06/30/25 - 1.06 03/31/25 - 1.29 Operating Margin 09/30/25 - -13.10 06/30/25 - -5.70 03/31/25 - -8.14 Net Margin 09/30/25 - -13.10 06/30/25 - -5.70 03/31/25 - -8.15 Pre-Tax Margin 09/30/25 - -12.08 06/30/25 - -4.85 03/31/25 - -6.99 Book Value 09/30/25 - 1.20 06/30/25 - 1.27 03/31/25 - 1.34 Inventory Turnover 09/30/25 - 3.63 06/30/25 - 2.97 03/31/25 - 2.72 Debt-to-Equity 09/30/25 - 0.03 06/30/25 - 0.03 03/31/25 - 0.02 Debt-to-Capital 09/30/25 - 2.91 06/30/25 - 3.23 03/31/25 - 2.17

Powered by Zacks Investment Research ©